Forus Raises $150M at $3B Valuation to Expand AI-Powered Prescription Network

U.S. healthcare technology startup Forus has raised $150 million in Series C funding at a $3 billion valuation, tripling its valuation in just four months as it expands an AI-powered network designed to help patients start and access prescribed treatments more efficiently.

The round was led by Bain Capital Ventures, which has backed Forus since its seed stage. All of the company's existing institutional investors also reinvested, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel.

The latest financing takes Forus' total funding beyond $300 million, just four months after the company, then known as Tandem, raised more than $160 million.

An AI agent for every prescription

Forus was founded in 2023 by Sahir Jaggi, a former Oscar Health executive who previously worked on healthcare strategy and patient experience.

The company's core idea is to address the gap between a doctor prescribing a medicine and a patient actually receiving and starting treatment.

According to Forus, nearly one-third of patients prescribed high-cost or complex medicines never take their first dose, while many others can wait weeks or months before beginning treatment.

Forus connects doctors, pharmacies, payers and biopharma companies through a single network. Each prescription is assigned an AI agent that can assess a patient's medical history, insurance coverage and financial circumstances.

The agent can then handle administrative processes such as prior authorisations, financial assistance applications and pharmacy routing.

The service is offered at no cost to providers or patients.

Building a nationwide healthcare network

Forus now operates across all 50 U.S. states and reaches patients in approximately 85% of residential ZIP codes nationwide.

The company says more than one-third of providers in its initial specialty use the platform, with adoption now expanding into additional specialties and care settings.

Forus also works with nine of the world's 15 largest biopharmaceutical companies, giving those companies visibility into where patients and healthcare providers encounter friction after a medicine reaches the market.

The company is positioning itself as an infrastructure layer between healthcare providers, patients and pharmaceutical companies.

Reducing the time between prescription and treatment

The company points to improvements in treatment access as evidence of its model.

Dr. Brinda Dixit, a rheumatologist at Virginia Rheumatology Clinic, said patients previously could wait two or three months to begin certain treatments. With Forus, she says medication approvals can return in less than two days, with patients starting treatment within one or two weeks.

The platform is therefore targeting an operational problem rather than attempting to replace physicians or diagnose diseases.

Its AI agents are focused on the administrative and logistical work that can prevent patients from accessing medicines that have already been prescribed.

A growing healthcare AI market

Forus is entering a rapidly expanding healthcare AI ecosystem.

OpenEvidence, for example, has built an AI-powered clinical search platform for physicians, while other healthcare companies are applying AI to insurance, care coordination and clinical workflows.

Forus is targeting a different part of the healthcare journey - the period after a prescription is written but before treatment begins.

That position also gives the company a connection across multiple stakeholders, including doctors, pharmacies, insurers and pharmaceutical manufacturers.

Funding the next phase

Forus plans to use the new $150 million to expand into additional medical specialties and care settings, increase the capabilities of its AI agents and grow its team.

The company's valuation has risen from roughly $1 billion to $3 billion in only four months, reflecting strong investor interest in AI infrastructure that can address operational problems within healthcare.

The next challenge will be scaling that model across more specialties while maintaining the reliability, regulatory compliance and healthcare partnerships required to operate across the U.S. system.

If Forus can successfully become the infrastructure connecting prescriptions to actual treatment, its ambition to place the platform in every doctor's office represents a potentially significant new category in healthcare AI.